Journal article
Antibodies to Plasmodium vivax reticulocyte binding protein 2b are associated with protection against P. vivax malaria in populations living in low malaria transmission regions of Brazil and Thailand
Wen-Qiang He, Stephan Karl, Michael T White, Wang Nguitragool, Wuelton Monteiro, Andrea Kuehn, Jakub Gruszczyk, Camila T Franca, Jetsumon Sattabongkot, Marcus VG Lacerda, Wai-Hong Tham, Ivo Mueller
PLOS NEGLECTED TROPICAL DISEASES | PUBLIC LIBRARY SCIENCE | Published : 2019
Abstract
BACKGROUND: The Plasmodium vivax Reticulocyte Binding Protein (PvRBP) family is involved in red blood cell recognition and members of this family are potential targets for antibodies that may block P. vivax invasion. To date, the acquisition of immunity against PvRBPs in low malaria transmission settings and in a broad age group of exposed individuals has not been investigated. METHODOLOGY/PRINCIPAL FINDINGS: Total IgG antibody levels to six members of the PvRBP family (PvRBP1a, PvRBP1b, PvRBP2a, PvRBP2b, a non-binding fragment of PvRBP2c (PvRBP2cNB) and PvRBP2-P2) were measured in samples collected from individuals living in two regions of low P. vivax endemicity in Brazil and Thailand. In ..
View full abstractGrants
Awarded by NHMRC fellowship
Awarded by Howard Hughes Medical Institute-Wellcome Trust
Awarded by National Health and Medical Research Council
Awarded by NHMRC Research Fellowship
Awarded by National Institutes of Health
Awarded by National Health & Medical Research Council
Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Funding Acknowledgements
W.Q.H. is supported by both Melbourne International Postgraduate Scholarship (MIPS) and Melbourne International Research Scholarship (MIRS), C.T.F is under the support of MIPS. S.K. is supported by an NHMRC fellowship (GNT1141441). M.V.G.L was supported by CNPq. W.H.T. is a Howard Hughes Medical Institute-Wellcome Trust International Research Scholar (208693/Z/17/Z) and funded by National Health and Medical Research Council (GNT1143187 and GNT 1160042). I.M. was supported by an NHMRC Research Fellowship (APP1043345). This work was supported by the TransEPI consortium (funded by the Bill & Melinda Gates Foundation), National Institutes of Health (Grant#5R01AI104822), the National Health & Medical Research Council (APP1102297 AND 1092789), and the Victorian State Government Operational Infrastructure Support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.